Literature DB >> 26000159

Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis.

Gaetano Vattemi1, Massimiliano Mirabella2, Valeria Guglielmi1, Matteo Lucchini2, Giuliano Tomelleri1, Anna Ghirardello3, Andrea Doria3.   

Abstract

The gold standard to characterize idiopathic inflammatory myopathies is the morphological, immunohistochemical and immunopathological analysis of muscle biopsy. Mononuclear cell infiltrates and muscle fiber necrosis are commonly shared histopathological features. Inflammatory cells that surround, invade and destroy healthy muscle fibers expressing MHC class I antigen are the typical pathological finding of polymyositis. Perifascicular atrophy and microangiopathy strongly support a diagnosis of dermatomyositis. Randomly distributed necrotic muscle fibers without mononuclear cell infiltrates represent the histopathological hallmark of immune-mediated necrotizing myopathy; meanwhile, endomysial inflammation and muscle fiber degeneration are the two main pathological features in sporadic inclusion body myositis. A correct differential diagnosis requires immunopathological analysis of the muscle biopsy and has important clinical implications for therapeutic approach. In particular, unnecessary, potentially harmful, immune-suppressive therapy should be avoided alike in dystrophic myopathies with secondary inflammation.

Entities:  

Keywords:  Autoimmune myositis; Differential diagnosis; Histopathology; Inflammatory myopathy

Year:  2014        PMID: 26000159      PMCID: PMC4386579          DOI: 10.1007/s13317-014-0062-2

Source DB:  PubMed          Journal:  Auto Immun Highlights        ISSN: 2038-0305


Introduction

Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of acquired muscle diseases, which have distinct clinical, pathological and histological features [1, 2]. The most common IIM seen in clinical practice can be separated into four categories including polymyositis (PM), dermatomyositis (DM), immune-mediated necrotizing myopathy (NM) and sporadic inclusion body myositis (sIBM) [1, 3]. In the diagnostic workup of an inflammatory myopathy, muscle biopsy is an indispensable and sensitive tool for establishing the diagnosis. Although all inflammatory myopathies have in common the presence of mononuclear cell infiltrates and muscle fiber necrosis, certain pathologic findings are unique for each subset.

Histopathology of polymyositis

The presence of mononuclear inflammatory cells that surround, invade and destroy healthy muscle fibers is the typical pathological finding of PM (Fig. 1a) [4]. These inflammatory cells consist predominantly of cytotoxic CD8+ T cells along with a lesser number of macrophages, only a few CD4+ T cells occur among the invading cells (Fig. 2) [4]. Muscle fibers surrounded by inflammatory cells express on their sarcolemma, the major histocompatibility complex (MHC) class I antigen, which is not constitutively expressed under normal conditions, but is ubiquitously upregulated on the surface of most fibers in PM (Fig. 1c) [4]. In addition, the cytotoxic CD8+ T cells invading morphologically normal-appearing muscle fibers have granules containing cytotoxic molecules including perforin and granzymes [4]. In PM, mononuclear cellular infiltrates may also occur in the perimysium and rarely at perivascular sites [4]. Nonspecific histological abnormalities consist of increased variation in fiber diameter, scattered necrotic and regenerating muscle fibers and increase in perimysial and/or endomysial connective tissue (Fig. 1b) [4]. Taken together these features strongly suggest that a cell-mediated cytotoxicity plays a key role in the pathogenesis of PM; according with this interpretation, clonally expanded CD8+ T cells invade muscle fibers expressing antigen-presenting MHC class I molecules and release cytotoxic granules, thus leading to myofiber necrosis [5].
Fig. 1

Polymyositis (muscle biopsy, hematoxylin and eosin staining). a A small endomysial inflammatory infiltrate surrounding and invading a healthy muscle fiber. b Scattered necrotic and regenerating muscle fibers. c MHC class I antigen is expressed on the sarcolemma of almost all muscle fibers

Fig. 2

Confocal fluorescence microscopical images of muscle biopsy from a PM patient. CD3+ T cells (green) surrounding two nonnecrotic muscle fibers are mainly CD8+ T cells (red)

Polymyositis (muscle biopsy, hematoxylin and eosin staining). a A small endomysial inflammatory infiltrate surrounding and invading a healthy muscle fiber. b Scattered necrotic and regenerating muscle fibers. c MHC class I antigen is expressed on the sarcolemma of almost all muscle fibers Confocal fluorescence microscopical images of muscle biopsy from a PM patient. CD3+ T cells (green) surrounding two nonnecrotic muscle fibers are mainly CD8+ T cells (red)

Histopathology of dermatomyositis

In DM, inflammatory infiltrates occur predominantly at perivascular sites or within the interfascicular septae (Fig. 3a), rarely in the endomysium, and are composed largely of B cells accompanied by CD4+ T helper cells, plasmacytoid dendritic cells and macrophages; CD8+ T cells are rare and NK cells sparse [4]. Single muscle fibers or clusters of muscle fibers in various stages of necrosis and/or regeneration are observed frequently [4]. The main pathological hallmark of DM is the distribution of atrophic, degenerating and regenerating fibers at the periphery of the fascicle (Fig. 3b); perifascicular atrophy involves both type 1 and type 2 muscle fibers, may affect two to ten layers and strongly support a diagnosis of DM, even in the absence of inflammation [4]. An early histological feature is the involvement of intramuscular blood vessels; the angiopathy is characterized by: (a) the deposition of immunoglobulins and complement, including the C5b-C9 membrane attack complex (MAC), on endomysial capillaries and small blood vessels and (b) the reduction in number of capillaries with endothelial hyperplasia and enlargement of the lumen of the remaining capillaries [6]. On electron microscopy, a unique ultrastructural alteration is the presence of tubuloreticular inclusions within the endothelial cytoplasm of arterioles and capillaries [7]. Therefore, DM is primarily considered a complement-mediated microangiopathy leading to capillary drop-out, necrosis of muscle fibers and perifascicular atrophy [5].
Fig. 3

Dermatomyositis (muscle biopsy, hematoxylin and eosin staining). a A large inflammatory infiltrate at perivascular site. b Prominent perifascicular atrophy

Dermatomyositis (muscle biopsy, hematoxylin and eosin staining). a A large inflammatory infiltrate at perivascular site. b Prominent perifascicular atrophy

Histopathology of immune-mediated necrotizing myopathy

Immune-mediated NM is an emerging entity characterized by a specific histological pattern [1–3, 5, 8]. The histopathological hallmark is the presence of randomly distributed necrotic muscle fibers along with fibers in various stages of regeneration, but in the absence of or sparse mononuclear cell infiltrates (Fig. 4) [1, 2, 5, 8]. Necrotic fibers can be invaded by macrophages which are the predominant mononuclear cell type, whereas T and B cells are virtually absent [1, 2, 5, 8]. MHC class I antigen is usually not expressed on the sarcolemma of muscle fibers and, if present, its expression is weak and focal [1, 2, 5, 8]. Deposition of MAC on intramuscular blood vessels has been reported only in a few cases [1, 2, 5, 8]. Therefore, in immune-mediated NM, muscle biopsy lacks the typical diagnostic features of DM and of PM. Immune-mediated NM is found in association with viral infections, connective tissue diseases, malignancy and statin therapy [5, 8]. Although the pathogenesis still remains elusive, the identification of specific antibodies in some patients with NM emphasizes an antibody-mediated mechanism underlying this disorder [5, 8].
Fig. 4

Immune-mediated necrotizing myopathy (muscle biopsy, hematoxylin and eosin staining): a few necrotic muscle fibers invaded by macrophages

Immune-mediated necrotizing myopathy (muscle biopsy, hematoxylin and eosin staining): a few necrotic muscle fibers invaded by macrophages

Histopathology of sporadic inclusion body myositis

In sIBM, the distribution and the immunophenotypic profile of the inflammatory cells are similar to those seen in PM, consisting predominantly of macrophages and CD8+ T cells which invade nonnecrotic muscle fibers that express MHC class I antigen on the sarcolemma [1, 5, 9, 10]. Besides endomysial inflammation, muscle biopsies from patients with sIBM show distinct light microscopic findings which include the following: (a) nonnecrotic muscle fibers containing one or more, irregular and various-sized vacuoles, most of them with basophilic granular deposits around the edges (rimmed vacuoles) (Fig. 5a, b); (b) eosinophilic cytoplasmic inclusions, usually near or in the vacuoles (Fig. 5a, b); (c) single or multiple intracellular amyloid deposits, usually in non-vacuolated areas and rarely within vacuoles, identified with fluorescence-enhanced Congo red staining (Fig. 5c); (d) mitochondrial abnormalities consisting of increased number of ragged red fibers (muscle fibers containing excessive mitochondrial proliferation) and of cytochrome c oxidase (COX)-negative fibers; (e) small angulated muscle fibers, which are considered indicative of a neurogenic process [1, 5, 9, 10]. Ultrastructural examination documents tubulofilamentous inclusions of 15–21 nm in the cytoplasm and/or in the nucleus of muscle fibers (Fig. 5d), referred to as paired helical filaments (PHFs), cytoplasmic 6–10 nm amyloid-like filaments and deposits of flocculomembranous and amorphous material [9, 10]. In addition, several proteins accumulate in muscle fibers of sIBM patients, including amyloid-β and its precursor protein AβPP, phosphorylated tau, ubiquitin, TDP-43, p62 and others [5, 9, 10]. However, none of these proteins can be considered a specific marker for a diagnosis of sIBM. To date, sIBM remains a complex and enigmatic muscle disorder, in which endomysial inflammation and muscle fiber degeneration are the two main pathological features, but the contribution of each to the pathogenesis is unknown [5, 9, 10].
Fig. 5

Sporadic inclusion body myositis (muscle biopsy, hematoxylin and eosin staining). a, b Rimmed vacuoles and eosinophilic inclusions in the cytoplasm of some muscle fibers. c Fluorescence-enhanced Congo red staining shows amyloid deposit within a vacuole. d (electron microscopy): several filamentous inclusions in the nucleus of muscle fiber

Sporadic inclusion body myositis (muscle biopsy, hematoxylin and eosin staining). a, b Rimmed vacuoles and eosinophilic inclusions in the cytoplasm of some muscle fibers. c Fluorescence-enhanced Congo red staining shows amyloid deposit within a vacuole. d (electron microscopy): several filamentous inclusions in the nucleus of muscle fiber

Differential diagnosis of idiopathic inflammatory myopathies

IIM include, in addition to the four main idiopathic forms (PM, DM, NM and sIBM), various diseases characterized by skeletal muscle inflammation, either primary or secondary to other causes. Main goal of IIM differential diagnosis is to accurately specify myositis type, ruling out mimics with secondary inflammatory changes (muscular dystrophies, metabolic, infectious, toxic or drug-induced myopathies) as well other neurological diseases (Table 1). Focal invasion by CD8+ T cells of nonnecrotic muscle fibers expressing MHC-I complex is the main diagnostic feature, since the CD8/MHC-1 complex is distinctive of IIM (Figs. 6, 7), differently from degenerative, toxic, necrotizing myopathies with secondary macrophagic infiltration. Diagnostic workup of myositis includes a comprehensive screening for medical conditions that may confound the diagnosis: anamnesis for iatrogenic myopathies, tests for autoimmunity, connective tissue diseases (CTD), systemic, endocrine and electrolytic abnormalities, electrophysiology and imaging studies [11].
Table 1

Main differential diagnosis of idiopathic myositis

Muscular dystrophiesMetabolic myopathies
 Facioscapulohumeral dystrophy (FSHD) Myophosphorylase deficiency
 Dysferlinopathies (LGMD2B, Miyoshi type) Adult-onset acid maltase deficiency
 Congenital dystrophies (merosin deficiency) Lipid storage myopathies
 Dystrophinopathies (Becker) Carnitine deficiency
 Mitochondrial myopathies
Endocrine myopathiesToxic/drug-induced myopathies
 Hypercorticosurrenalism Statin-induced myopathies
 Hyper/hypothyroidism Antiretroviral drug myopathy
 Hyper/hypoparathyroidism Steroid myopathy
 Others: antibiotics, chinidine, D-penicillamine, procainamide, FANS, TNF and H+ pump inhibitors
Non-muscular diseasesSystemic disorder-associated myopathies
 Guillain–Barrè syndromeNutritional deficits associated myopathy (alcoholism, malabsorption)
 Transverse myelitisElectrolyte imbalance myopathies (hypophosphatemia, hypomagnesemia, hypokalemia)
 Neuromuscular junction pathology (myasthenia gravis, Lambert–Eaton syndrome)Critical illness myopathy (CIM)
 Rheumatic diseases, fibromyalgiaCancer-associated myopathies (disuse, cachexia, drug-induced, paraneoplastic neuromyopathy)
 Periodic paralysis
Fig. 6

Endomysial CD8+ T lymphocytes surrounding partially invaded and apparently not invaded muscle fibers in a muscle biopsy of a patient with sporadic inclusion body myositis (IBM). All muscle fibers and inflammatory cells display a strong MHC-I immunoreactivity

Fig. 7

Diffuse MHC-I sarcolemmal immunoreactivity in a muscle biopsy of a patient with polymyositis (PM) (upper panels). On the contrary in necrotizing autoimmune myopathy (NAM), MHC-I is expressed only on membrane and/or sarcoplasm of necrotic fibers, by endomysial macrophages besides, as normal finding, in muscle blood vessels (lower panels)

Main differential diagnosis of idiopathic myositis Endomysial CD8+ T lymphocytes surrounding partially invaded and apparently not invaded muscle fibers in a muscle biopsy of a patient with sporadic inclusion body myositis (IBM). All muscle fibers and inflammatory cells display a strong MHC-I immunoreactivity Diffuse MHC-I sarcolemmal immunoreactivity in a muscle biopsy of a patient with polymyositis (PM) (upper panels). On the contrary in necrotizing autoimmune myopathy (NAM), MHC-I is expressed only on membrane and/or sarcoplasm of necrotic fibers, by endomysial macrophages besides, as normal finding, in muscle blood vessels (lower panels) Immune-mediated NM, besides to be associated with autoantibodies such as anti-SRP or anti-HMGCoA reductase [12], is often related to drug exposition (statins), CTD or neoplastic diseases [13]. Brachio-cervical myositis (BCM) is a rare form of IIM, responsive to steroids, clinically characterized by proximal muscle weakness mainly involving cervical and shoulder girdle muscles with dysphagia. Histologically BCM presents typical perivascular inflammatory infiltrates largely composed by B lymphocytes [14] (Fig. 8).
Fig. 8

MHC-I is highly expressed on sarcolemmal of all muscle fibers and in mononuclear cells of a large perivascular infiltrate in a muscle biopsy of a patient with brachio-cervical inflammatory myopathy (BCM). The vast majority of the inflammatory cells are CD20+ B lymphocytes

MHC-I is highly expressed on sarcolemmal of all muscle fibers and in mononuclear cells of a large perivascular infiltrate in a muscle biopsy of a patient with brachio-cervical inflammatory myopathy (BCM). The vast majority of the inflammatory cells are CD20+ B lymphocytes Eosinophilia in peripheral blood or within muscle biopsy, fascial involvement, and muscle pain suggest the presence of eosinophilic myositis. Eosinophilia-associated myopathies include a focal usually benign eosinophilic myositis, eosinophilic perimyositis mostly associated with fasciitis and eosinophilic polymyositis that can be idiopathic (to be distinguished by LMGD2A due to calpain-3 gene mutation) or occurring as a feature of multiorgan hypereosinophilic syndrome (parasitic infections, CTD, hematologic malignancies, drugs, toxics) [15]. In presence of hypereosinophilia, myalgias and focal muscle swelling, parasitic infections by protozoa, cestodes or nematodes (toxoplasmosis, trypanosomiasis, echinococcosis, trichinosis, cysticercosis) must be ruled out by parasite identification on muscle biopsy and serologic findings. Granulomatous myositis can occur during systemic diseases such as sarcoidosis or as idiopathic form clinically similar to classical IIM but histologically characterized by epithelioid and Langhans giant cells to form epithelioid granulomas [16]. Serum/urine immunofixation may detect a monoclonal gammopathy in patients with a severe sporadic late-onset nemaline bodies’ myopathy (SLONM). SLONM shows clinical and electromyographic features similar to IIM, moderate elevation of creatine phosphokinase (CPK) and fibers containing nemaline bodies visible with Trichrome staining, usually with no inflammation on muscle biopsy [17]. In HIV patients, a zidovudine-induced mitochondrial myopathy may coexist with HIV-induced T cell-mediated myositis. Inflammatory changes may be found on muscle biopsy of patients treated with procainamide, D-penicillamine (DM-like), α-interferon (PM-like), while chloroquine and amiodarone may induce cytoplasmic vacuoles and fiber necrosis. Drugs affecting microtubules (colchicine and vincristine) also provoke myopathic changes with autophagic vacuoles in muscle fibers. It is important to identify a steroid myopathy presenting with subacute proximal muscle weakness and type II fibers atrophy. When occurring during IIM treatment, it may be mistaken as an exacerbation leading to more aggressive steroid treatment rather than its discontinuation. Thyroid evaluation is needed because hypothyroidism can cause proximal muscle weakness and enzymes elevation with myoedema and pseudohypertrophy, usually without lymphomonocitic infiltrates and isolated necrosis that may be found instead in hyperthyroidism [18]. Hypercortisolism and hyper/hypoparathyroidism can also induce the onset of a subacute myopathy. Diabetes may sometimes be complicated by skeletal muscle ischemia/infarction, beginning acutely with focal muscle pain, swelling and weakness in proximal lower limb muscles. Genetic defects in dysferlin gene cause LGMD2B or a distal muscular dystrophy (Miyoshi phenotype): a relatively acute onset of pelvifemoral weakness in early 20 s with elevated CPK levels may suggest a PM. Serum CPK levels may be very high during active phase and biopsy shows significant mononuclear cell infiltration with dystrophic changes and small sarcolemmal defects with thickened basal lamina. A significant number of muscle biopsies from patients with facioscapulohumeral dystrophy (FSHD) show inflammatory changes. FSHD differentiates from IIM because of typically selective asymmetric muscle involvement of facial and shoulder muscles; weakness and molecular studies will confirm diagnosis. Female carrier of dystrophinopathy can present CPK increase, adult-onset proximal muscle weakness with inflammatory alterations on biopsy [19]. A typical mosaic of positive and negative fibers is seen on dystrophin immunostaining. Milder forms of Becker muscular dystrophy with high CPK, myalgias, cramps, exercise intolerance, and mild limb-girdle weakness (quadriceps myopathy) mimic IIM because of endomysial inflammation; Western blot for muscle dystrophin is required because immunohistochemistry may be normal. Sarcoglycanopathies (LGMD types IIC to IIF) start in childhood as pelvic muscle weakness with high levels of CPK and marked regeneration and necrosis on biopsy. Early evaluation of these patients may raise the suspect of subacute myositis, till immunohistochemical and molecular studies demonstrate the correct diagnosis. Inherited metabolic myopathies, with intermittent episodes of acute muscle pain and tenderness exertion-induced, such as type V and VII glycogenosis, rarely present as adult-onset muscle weakness with fatigue and exercise intolerance. Forearm lactate test and determination of muscular enzymatic activity are fundamental for diagnosis. Adult-onset acid maltase deficiency (AMD, type II glycogenosis) presents as progressive myopathy resembling PM with early diaphragmatic involvement. Muscle biopsy often demonstrates a vacuolar myopathy with increased glycogen and lysosomal activation [20]. Mitochondrial myopathies are extremely heterogeneous but may evocate IIM when presenting as symmetric proximal myopathy. Familiar recurrence with maternal inheritance, presence of ophthalmoplegia and systemic involvement helps in diagnosis. Muscle biopsy shows abnormalities of COX/SDH stainings, such as ragged red fibers. A correct differential diagnosis has important clinical implication: identification of myositis type such as NM, even if steroid resistant, supports the decision to boost immunosuppression, while specific therapies are available for some genetic myopathies (AMD, some lipidosis) and unnecessary, potentially harmful, immune-suppressive therapy should be avoided alike in dystrophic myopathies with secondary inflammation.

Conclusions

Histopathologic features at muscle biopsy, related to the knowledge of disease-specific pathomechanisms, are essential in the diagnostic workup of IIM. The characteristic histopathological features, usually shared by the different forms of immune-mediated IIM, are the presence of mononuclear cell infiltrates and muscle fiber necrosis. Muscle immunohistochemical analysis and cell phenotyping are recommended to achieve correct diagnosis and proper therapeutic intervention.
  19 in total

1.  119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands.

Authors:  Jessica E Hoogendijk; Anthony A Amato; Bryan R Lecky; Ernest H Choy; Ingrid E Lundberg; Michael R Rose; Jiri Vencovsky; Marianne de Visser; Richard A Hughes
Journal:  Neuromuscul Disord       Date:  2004-05       Impact factor: 4.296

Review 2.  Necrotizing autoimmune myopathy.

Authors:  Christina Liang; Merrilee Needham
Journal:  Curr Opin Rheumatol       Date:  2011-11       Impact factor: 5.006

Review 3.  Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis.

Authors:  Valerie Askanas; W King Engel; Anna Nogalska
Journal:  J Neuropathol Exp Neurol       Date:  2012-08       Impact factor: 3.685

Review 4.  Dermatomyositis, polymyositis and immune-mediated necrotising myopathies.

Authors:  Yue-Bei Luo; Frank L Mastaglia
Journal:  Biochim Biophys Acta       Date:  2014-06-05

Review 5.  Review: An update on inflammatory and autoimmune myopathies.

Authors:  M C Dalakas
Journal:  Neuropathol Appl Neurobiol       Date:  2011-04       Impact factor: 8.090

6.  Toward deconstructing the phenotype of late-onset Pompe disease.

Authors:  Angela Schüller; Stephan Wenninger; Nicola Strigl-Pill; Benedikt Schoser
Journal:  Am J Med Genet C Semin Med Genet       Date:  2012-01-17       Impact factor: 3.908

Review 7.  Eosinophilic myositis: an updated review.

Authors:  A Selva-O'Callaghan; E Trallero-Araguás; J M Grau
Journal:  Autoimmun Rev       Date:  2014-01-11       Impact factor: 9.754

Review 8.  Review: immune-mediated necrotizing myopathies--a heterogeneous group of diseases with specific myopathological features.

Authors:  W Stenzel; H-H Goebel; E Aronica
Journal:  Neuropathol Appl Neurobiol       Date:  2012-12       Impact factor: 8.090

9.  Carrier woman of Duchenne muscular dystrophy mimicking inflammatory myositis.

Authors:  Jiyeol Yoon; Se Hoon Kim; Chang-Seok Ki; Min-Jung Kwon; Mie-Jin Lim; Seong-Ryul Kwon; Kowoon Joo; Chang-Gi Moon; Won Park
Journal:  J Korean Med Sci       Date:  2011-03-28       Impact factor: 2.153

Review 10.  Is it really myositis? A consideration of the differential diagnosis.

Authors:  Niranjanan Nirmalananthan; Janice L Holton; Michael G Hanna
Journal:  Curr Opin Rheumatol       Date:  2004-11       Impact factor: 5.006

View more
  22 in total

1.  Immunohistochemical and ultrastructural analysis of sporadic inclusion body myositis: a case series.

Authors:  Katarzyna Haczkiewicz; Agata Sebastian; Aleksandra Piotrowska; Maria Misterska-Skóra; Agnieszka Hałoń; Marta Skoczyńska; Maciej Sebastian; Piotr Wiland; Piotr Dzięgiel; Marzenna Podhorska-Okołów
Journal:  Rheumatol Int       Date:  2018-12-08       Impact factor: 2.631

2.  Paraneoplastic Necrotizing Myopathy Post Lumpectomy and Chemotherapy for Early Breast Cancer.

Authors:  Priyanka Venkatesh; Sophia M Hitchcock; Jamie Jacobsohn; Anup Kasi
Journal:  Cureus       Date:  2020-10-12

3.  Long-term Follow-up and Muscle Imaging Findings in Brachio-Cervical Inflammatory Myopathy.

Authors:  Matteo Lucchini; Sara Bortolani; Mauro Monforte; Manuela Papacci; Enzo Ricci; Massimiliano Mirabella; Giorgio Tasca
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-05-19

Review 4.  Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies.

Authors:  Boel De Paepe; Jana Zschüntzsch
Journal:  Int J Mol Sci       Date:  2015-08-11       Impact factor: 5.923

5.  Immunopathological Features of Canine Myocarditis Associated with Leishmania infantum Infection.

Authors:  Alessandro Costagliola; Giuseppe Piegari; Iwona Otrocka-Domagala; Davide Ciccarelli; Valentina Iovane; Gaetano Oliva; Valeria Russo; Laura Rinaldi; Serenella Papparella; Orlando Paciello
Journal:  Biomed Res Int       Date:  2016-06-19       Impact factor: 3.411

6.  Development and evaluation of a standardized ELISA for the determination of autoantibodies against cN-1A (Mup44, NT5C1A) in sporadic inclusion body myositis.

Authors:  Sabine L Kramp; Dmitry Karayev; Guo Shen; Allan L Metzger; Robert I Morris; Eugene Karayev; Yvonne Lam; Richard M Kazdan; Ger J M Pruijn; Sandra Saschenbrecker; Cornelia Dähnrich; Wolfgang Schlumberger
Journal:  Auto Immun Highlights       Date:  2016-11-17

7.  Myositis, Ganglioneuritis, and Myocarditis with Distinct Perifascicular Muscle Atrophy in a 2-Year-Old Male Boxer.

Authors:  Paul M Rossman; Stephanie A Thomovsky; Ryan M Schafbuch; Ling T Guo; G D Shelton
Journal:  Front Vet Sci       Date:  2018-02-20

8.  MRI of skeletal muscles in patients with idiopathic inflammatory myopathies: characteristic findings and diagnostic performance in dermatomyositis.

Authors:  Taro Ukichi; Ken Yoshida; Satoshi Matsushima; Go Kawakami; Kentaro Noda; Kazuhiro Furuya; Daitaro Kurosaka
Journal:  RMD Open       Date:  2019-03-28

9.  Pervasive inflammatory activation in patients with deficiency in very-long-chain acyl-coA dehydrogenase (VLCADD).

Authors:  Abbe N Vallejo; Henry J Mroczkowski; Joshua J Michel; Michael Woolford; Harry C Blair; Patricia Griffin; Elizabeth McCracken; Stephanie J Mihalik; Miguel Reyes-Mugica; Jerry Vockley
Journal:  Clin Transl Immunology       Date:  2021-06-27

Review 10.  Mediators and Patterns of Muscle Loss in Chronic Systemic Inflammation.

Authors:  Sandra Pérez-Baos; Iván Prieto-Potin; Jorge A Román-Blas; Olga Sánchez-Pernaute; Raquel Largo; Gabriel Herrero-Beaumont
Journal:  Front Physiol       Date:  2018-04-24       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.